Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry
Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited. To study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment-refractory atopic dermatitis. Patients treated with dupilumab and p...
Gespeichert in:
| Veröffentlicht in: | Journal of the American Academy of Dermatology 2021-04, Vol.84 (4), p.1000-1009 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1009 |
|---|---|
| container_issue | 4 |
| container_start_page | 1000 |
| container_title | Journal of the American Academy of Dermatology |
| container_volume | 84 |
| creator | Ariëns, Lieneke F.M. van der Schaft, Jorien Spekhorst, Lotte S. Bakker, Daphne S. Romeijn, Geertruida L.E. Kouwenhoven, Tessa A. Kamsteeg, Marijke Voorberg, Angelique N. Oosting, Albert J. de Ridder, Ilona Sloeserwij, Annemieke Haeck, Inge Thijs, Judith L. Schuttelaar, Marie L.A. de Bruin-Weller, Marjolein S. |
| description | Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited.
To study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment-refractory atopic dermatitis.
Patients treated with dupilumab and participating in the Dutch BioDay registry were included. Clinical effectiveness and safety were evaluated.
Two hundred ten atopic dermatitis patients were included. Mean percentage change in Eczema Area and Severity Index score after 16 weeks was –70.0% (standard deviation 33.2%) and further decreased to –76.6% (standard deviation 30.6%) by week 52. A greater than or equal to 75% improvement in the score was achieved by 59.9% of individuals by week 16 and by 70.3% by week 52. The most reported adverse effect was conjunctivitis (34%). Limited patients (17; 8.1%) discontinued dupilumab treatment.
Because of the lack of a control group and observational design, factors of bias may have been induced.
Treatment with dupilumab resulted in a rapid improvement in clinical outcome measures, and effectiveness further improved during the 52-week follow-up period. |
| doi_str_mv | 10.1016/j.jaad.2020.08.127 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2444382688</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0190962220326189</els_id><sourcerecordid>2444382688</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-1bee9c421177acf930cc9e21d91f4a2d081fd214e7d7cba4d1d93943a0a982c53</originalsourceid><addsrcrecordid>eNp9kT2P1DAQhi0E4paDP0CBXNIk2I4vjhENd8uXdBINiNKatSe7XpI42M6h_Cl-I172oKSaYp55pXkfQp5zVnPG21fH-gjgasEEq1lXc6EekA1nWlWt6tRDsmFcs0q3QlyQJykdGWNaNuoxuWiElq1u1Yb82i6zH5YRdjQdws9EhzDtq4xxpNj3aLO_wwlTon6iQAeIe6Q2HELMNPQ0R4Q84pSriH0Em0NcKeQwe0tdyYDss090LrNAf0Ic-GGl8wn2Fl_TK1F9Q_xOI6ZlKEgfw0jzAel2yfZAr33Ywlq2e59yXJ-SRz0MCZ_dz0vy9f27Lzcfq9vPHz7dvL2trGQsV3yHqK0UnCsFttcNs1aj4E7zXoJwrOO9E1yicsruQLqyaUo3wEB3wl41l-TlOXeO4ceCKZvRJ4vDABOGJRkhpWw60XZdQcUZtTGkVHowc_QjxNVwZk6ezNGcPJmTJ8M6UzyVoxf3-ctuRPfv5K-YArw5A1i-vPMYTbKlQ4vOx2LFuOD_l_8b2ZmoIA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2444382688</pqid></control><display><type>article</type><title>Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry</title><source>Elsevier ScienceDirect Journals</source><creator>Ariëns, Lieneke F.M. ; van der Schaft, Jorien ; Spekhorst, Lotte S. ; Bakker, Daphne S. ; Romeijn, Geertruida L.E. ; Kouwenhoven, Tessa A. ; Kamsteeg, Marijke ; Voorberg, Angelique N. ; Oosting, Albert J. ; de Ridder, Ilona ; Sloeserwij, Annemieke ; Haeck, Inge ; Thijs, Judith L. ; Schuttelaar, Marie L.A. ; de Bruin-Weller, Marjolein S.</creator><creatorcontrib>Ariëns, Lieneke F.M. ; van der Schaft, Jorien ; Spekhorst, Lotte S. ; Bakker, Daphne S. ; Romeijn, Geertruida L.E. ; Kouwenhoven, Tessa A. ; Kamsteeg, Marijke ; Voorberg, Angelique N. ; Oosting, Albert J. ; de Ridder, Ilona ; Sloeserwij, Annemieke ; Haeck, Inge ; Thijs, Judith L. ; Schuttelaar, Marie L.A. ; de Bruin-Weller, Marjolein S.</creatorcontrib><description>Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited.
To study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment-refractory atopic dermatitis.
Patients treated with dupilumab and participating in the Dutch BioDay registry were included. Clinical effectiveness and safety were evaluated.
Two hundred ten atopic dermatitis patients were included. Mean percentage change in Eczema Area and Severity Index score after 16 weeks was –70.0% (standard deviation 33.2%) and further decreased to –76.6% (standard deviation 30.6%) by week 52. A greater than or equal to 75% improvement in the score was achieved by 59.9% of individuals by week 16 and by 70.3% by week 52. The most reported adverse effect was conjunctivitis (34%). Limited patients (17; 8.1%) discontinued dupilumab treatment.
Because of the lack of a control group and observational design, factors of bias may have been induced.
Treatment with dupilumab resulted in a rapid improvement in clinical outcome measures, and effectiveness further improved during the 52-week follow-up period.</description><identifier>ISSN: 0190-9622</identifier><identifier>EISSN: 1097-6787</identifier><identifier>DOI: 10.1016/j.jaad.2020.08.127</identifier><identifier>PMID: 32946967</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>atopic dermatitis ; daily practice ; disease severity ; dupilumab ; effectiveness ; long-term ; safety</subject><ispartof>Journal of the American Academy of Dermatology, 2021-04, Vol.84 (4), p.1000-1009</ispartof><rights>2020</rights><rights>Copyright © 2020. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-1bee9c421177acf930cc9e21d91f4a2d081fd214e7d7cba4d1d93943a0a982c53</citedby><cites>FETCH-LOGICAL-c400t-1bee9c421177acf930cc9e21d91f4a2d081fd214e7d7cba4d1d93943a0a982c53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0190962220326189$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32946967$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ariëns, Lieneke F.M.</creatorcontrib><creatorcontrib>van der Schaft, Jorien</creatorcontrib><creatorcontrib>Spekhorst, Lotte S.</creatorcontrib><creatorcontrib>Bakker, Daphne S.</creatorcontrib><creatorcontrib>Romeijn, Geertruida L.E.</creatorcontrib><creatorcontrib>Kouwenhoven, Tessa A.</creatorcontrib><creatorcontrib>Kamsteeg, Marijke</creatorcontrib><creatorcontrib>Voorberg, Angelique N.</creatorcontrib><creatorcontrib>Oosting, Albert J.</creatorcontrib><creatorcontrib>de Ridder, Ilona</creatorcontrib><creatorcontrib>Sloeserwij, Annemieke</creatorcontrib><creatorcontrib>Haeck, Inge</creatorcontrib><creatorcontrib>Thijs, Judith L.</creatorcontrib><creatorcontrib>Schuttelaar, Marie L.A.</creatorcontrib><creatorcontrib>de Bruin-Weller, Marjolein S.</creatorcontrib><title>Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry</title><title>Journal of the American Academy of Dermatology</title><addtitle>J Am Acad Dermatol</addtitle><description>Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited.
To study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment-refractory atopic dermatitis.
Patients treated with dupilumab and participating in the Dutch BioDay registry were included. Clinical effectiveness and safety were evaluated.
Two hundred ten atopic dermatitis patients were included. Mean percentage change in Eczema Area and Severity Index score after 16 weeks was –70.0% (standard deviation 33.2%) and further decreased to –76.6% (standard deviation 30.6%) by week 52. A greater than or equal to 75% improvement in the score was achieved by 59.9% of individuals by week 16 and by 70.3% by week 52. The most reported adverse effect was conjunctivitis (34%). Limited patients (17; 8.1%) discontinued dupilumab treatment.
Because of the lack of a control group and observational design, factors of bias may have been induced.
Treatment with dupilumab resulted in a rapid improvement in clinical outcome measures, and effectiveness further improved during the 52-week follow-up period.</description><subject>atopic dermatitis</subject><subject>daily practice</subject><subject>disease severity</subject><subject>dupilumab</subject><subject>effectiveness</subject><subject>long-term</subject><subject>safety</subject><issn>0190-9622</issn><issn>1097-6787</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kT2P1DAQhi0E4paDP0CBXNIk2I4vjhENd8uXdBINiNKatSe7XpI42M6h_Cl-I172oKSaYp55pXkfQp5zVnPG21fH-gjgasEEq1lXc6EekA1nWlWt6tRDsmFcs0q3QlyQJykdGWNaNuoxuWiElq1u1Yb82i6zH5YRdjQdws9EhzDtq4xxpNj3aLO_wwlTon6iQAeIe6Q2HELMNPQ0R4Q84pSriH0Em0NcKeQwe0tdyYDss090LrNAf0Ic-GGl8wn2Fl_TK1F9Q_xOI6ZlKEgfw0jzAel2yfZAr33Ywlq2e59yXJ-SRz0MCZ_dz0vy9f27Lzcfq9vPHz7dvL2trGQsV3yHqK0UnCsFttcNs1aj4E7zXoJwrOO9E1yicsruQLqyaUo3wEB3wl41l-TlOXeO4ceCKZvRJ4vDABOGJRkhpWw60XZdQcUZtTGkVHowc_QjxNVwZk6ezNGcPJmTJ8M6UzyVoxf3-ctuRPfv5K-YArw5A1i-vPMYTbKlQ4vOx2LFuOD_l_8b2ZmoIA</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Ariëns, Lieneke F.M.</creator><creator>van der Schaft, Jorien</creator><creator>Spekhorst, Lotte S.</creator><creator>Bakker, Daphne S.</creator><creator>Romeijn, Geertruida L.E.</creator><creator>Kouwenhoven, Tessa A.</creator><creator>Kamsteeg, Marijke</creator><creator>Voorberg, Angelique N.</creator><creator>Oosting, Albert J.</creator><creator>de Ridder, Ilona</creator><creator>Sloeserwij, Annemieke</creator><creator>Haeck, Inge</creator><creator>Thijs, Judith L.</creator><creator>Schuttelaar, Marie L.A.</creator><creator>de Bruin-Weller, Marjolein S.</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202104</creationdate><title>Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry</title><author>Ariëns, Lieneke F.M. ; van der Schaft, Jorien ; Spekhorst, Lotte S. ; Bakker, Daphne S. ; Romeijn, Geertruida L.E. ; Kouwenhoven, Tessa A. ; Kamsteeg, Marijke ; Voorberg, Angelique N. ; Oosting, Albert J. ; de Ridder, Ilona ; Sloeserwij, Annemieke ; Haeck, Inge ; Thijs, Judith L. ; Schuttelaar, Marie L.A. ; de Bruin-Weller, Marjolein S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-1bee9c421177acf930cc9e21d91f4a2d081fd214e7d7cba4d1d93943a0a982c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>atopic dermatitis</topic><topic>daily practice</topic><topic>disease severity</topic><topic>dupilumab</topic><topic>effectiveness</topic><topic>long-term</topic><topic>safety</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ariëns, Lieneke F.M.</creatorcontrib><creatorcontrib>van der Schaft, Jorien</creatorcontrib><creatorcontrib>Spekhorst, Lotte S.</creatorcontrib><creatorcontrib>Bakker, Daphne S.</creatorcontrib><creatorcontrib>Romeijn, Geertruida L.E.</creatorcontrib><creatorcontrib>Kouwenhoven, Tessa A.</creatorcontrib><creatorcontrib>Kamsteeg, Marijke</creatorcontrib><creatorcontrib>Voorberg, Angelique N.</creatorcontrib><creatorcontrib>Oosting, Albert J.</creatorcontrib><creatorcontrib>de Ridder, Ilona</creatorcontrib><creatorcontrib>Sloeserwij, Annemieke</creatorcontrib><creatorcontrib>Haeck, Inge</creatorcontrib><creatorcontrib>Thijs, Judith L.</creatorcontrib><creatorcontrib>Schuttelaar, Marie L.A.</creatorcontrib><creatorcontrib>de Bruin-Weller, Marjolein S.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American Academy of Dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ariëns, Lieneke F.M.</au><au>van der Schaft, Jorien</au><au>Spekhorst, Lotte S.</au><au>Bakker, Daphne S.</au><au>Romeijn, Geertruida L.E.</au><au>Kouwenhoven, Tessa A.</au><au>Kamsteeg, Marijke</au><au>Voorberg, Angelique N.</au><au>Oosting, Albert J.</au><au>de Ridder, Ilona</au><au>Sloeserwij, Annemieke</au><au>Haeck, Inge</au><au>Thijs, Judith L.</au><au>Schuttelaar, Marie L.A.</au><au>de Bruin-Weller, Marjolein S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry</atitle><jtitle>Journal of the American Academy of Dermatology</jtitle><addtitle>J Am Acad Dermatol</addtitle><date>2021-04</date><risdate>2021</risdate><volume>84</volume><issue>4</issue><spage>1000</spage><epage>1009</epage><pages>1000-1009</pages><issn>0190-9622</issn><eissn>1097-6787</eissn><abstract>Real-life data on long-term effectiveness and safety of dupilumab in atopic dermatitis patients are limited.
To study 52-week effectiveness and safety of dupilumab in a prospective multicenter cohort of adult patients with treatment-refractory atopic dermatitis.
Patients treated with dupilumab and participating in the Dutch BioDay registry were included. Clinical effectiveness and safety were evaluated.
Two hundred ten atopic dermatitis patients were included. Mean percentage change in Eczema Area and Severity Index score after 16 weeks was –70.0% (standard deviation 33.2%) and further decreased to –76.6% (standard deviation 30.6%) by week 52. A greater than or equal to 75% improvement in the score was achieved by 59.9% of individuals by week 16 and by 70.3% by week 52. The most reported adverse effect was conjunctivitis (34%). Limited patients (17; 8.1%) discontinued dupilumab treatment.
Because of the lack of a control group and observational design, factors of bias may have been induced.
Treatment with dupilumab resulted in a rapid improvement in clinical outcome measures, and effectiveness further improved during the 52-week follow-up period.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32946967</pmid><doi>10.1016/j.jaad.2020.08.127</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0190-9622 |
| ispartof | Journal of the American Academy of Dermatology, 2021-04, Vol.84 (4), p.1000-1009 |
| issn | 0190-9622 1097-6787 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2444382688 |
| source | Elsevier ScienceDirect Journals |
| subjects | atopic dermatitis daily practice disease severity dupilumab effectiveness long-term safety |
| title | Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T23%3A17%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dupilumab%20shows%20long-term%20effectiveness%20in%20a%20large%20cohort%20of%20treatment-refractory%20atopic%20dermatitis%20patients%20in%20daily%20practice:%2052-Week%20results%20from%20the%20Dutch%20BioDay%20registry&rft.jtitle=Journal%20of%20the%20American%20Academy%20of%20Dermatology&rft.au=Ari%C3%ABns,%20Lieneke%20F.M.&rft.date=2021-04&rft.volume=84&rft.issue=4&rft.spage=1000&rft.epage=1009&rft.pages=1000-1009&rft.issn=0190-9622&rft.eissn=1097-6787&rft_id=info:doi/10.1016/j.jaad.2020.08.127&rft_dat=%3Cproquest_cross%3E2444382688%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2444382688&rft_id=info:pmid/32946967&rft_els_id=S0190962220326189&rfr_iscdi=true |